Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • NextGenSeq
    Senior Member
    • Apr 2009
    • 482

    #76
    We got an invitation too.

    Comment

    • GenoMax
      Senior Member
      • Feb 2008
      • 7142

      #77
      @NextGenSeq and @ZFHans: Does the "invitation" say when you are likely to actually get the kits?

      Comment

      • ZFHans
        Member
        • Jun 2009
        • 10

        #78
        The invitation is specific to the point of: "we look forward to working with you in the coming weeks."
        More details will follow on the portal website that they have set up.

        Comment

        • gringer
          David Eccles (gringer)
          • May 2011
          • 845

          #79
          There's a fair bit of information on the Nanopore website now:



          Here's my rough summary:
          • Restricted open-access philosophy for results and software development via login at nanoporeonline.com
          • 6 week MAP cycles, 2 weeks for configuration, 4 for your own experiments. Burn-in cell in week 1, two experimental flow cells delivered week 3, two more week 5
          • Can duck out at any time with a deposit refund
          • Can continue on in the program for the next cycle, or stop and give someone else a go
          • Cost is $1,000 deposit (covers all MAP cycles) + $250 delivery (per cycle for multiple deliveries & returns) + taxes where relevant
          • ONP receives diagnostic statistics via the Grouper instrument software, but results are yours to keep
          • ONP requests that people remain tight-lipped until the end of the burn-in period, so people will be quiet about this for at least the next couple of weeks
          • Computer requirements are not mentioned on this page, although it is stated that Macs are not yet fully supported

          Comment

          • Jeremy
            Senior Member
            • Nov 2009
            • 190

            #80
            Unfortunately my email was:

            Thank you very much for taking the time to apply to join the MinION Access programme (MAP). We received a large number of applications from a broad range of applicants and unfortunately cannot invite every applicant at this time. Unfortunately we cannot offer you a place in the first wave of MAP however we intend to make more places available in the future and hope that you are happy to remain on our list of interested participants.
            Once again we thank you for your interest. If you would prefer not to be considered for MAP in the future please email us on [email protected].

            I hope those of us that did get in keep everyone posted in this thread.

            Comment

            • ymc
              Senior Member
              • Mar 2010
              • 496

              #81
              I just noticed Oxford Nanopore thinks solid state nanopore is the future. They added Harvard's solid state nanopore team in 2011. If this new team develops fast enough, the current gen of protein nanopore might just be a stopgap product?

              Comment

              Latest Articles

              Collapse

              • SEQadmin2
                Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
                by SEQadmin2


                Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

                The systematic characterization of the human proteome has
                ...
                07-20-2026, 11:48 AM
              • SEQadmin2
                Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
                by SEQadmin2



                Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
                ...
                07-09-2026, 11:10 AM
              • SEQadmin2
                Cancer Drug Resistance: The Lingering Barrier to Rising Survival
                by SEQadmin2



                Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

                There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
                07-08-2026, 05:17 AM

              ad_right_rmr

              Collapse

              News

              Collapse

              Topics Statistics Last Post
              Started by SEQadmin2, 07-24-2026, 12:17 PM
              0 responses
              19 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 07-23-2026, 11:41 AM
              0 responses
              19 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 07-20-2026, 11:10 AM
              0 responses
              25 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 07-13-2026, 10:26 AM
              0 responses
              38 views
              0 reactions
              Last Post SEQadmin2  
              Working...